AbbVie Inc. (ABBV) forty fourth Annual J.P. Morgan Healthcare Convention January 14, 2026 11:15 AM EST
Firm Contributors
Scott Reents – Government VP & CFO
Jeffrey Stewart – Government VP & Chief Business Officer
Roopal Thakkar – Government VP of Analysis and Improvement & Chief Scientific Officer
Convention Name Contributors
Christopher Schott – JPMorgan Chase & Co, Analysis Division
Presentation
Christopher Schott
JPMorgan Chase & Co, Analysis Division
Good morning, everyone. I am Chris Schott at JPMorgan, and it is my pleasure to be internet hosting this fireplace chat immediately with AbbVie. From the corporate, we’ve Scott Reents, CFO; Jeff Stewart, Chief Business Officer; and Roopal Thakkar, Chief Medical Officer. So glad New 12 months guys, and thanks for becoming a member of immediately.
Query-and-Reply Session
Christopher Schott
JPMorgan Chase & Co, Analysis Division
I assumed simply to kick off the dialog, Scott. As we enter 2026, are you able to simply run by high priorities for AbbVie and the way you are enthusiastic about the enterprise?
Scott Reents
Government VP & CFO
Certain. Nice. Thanks for having us, Chris. We’re very excited to be right here immediately and to speak about AbbVie. So after we have a look at 2026, I’d say it is actually a continuation of the technique that we have been articulating. One is simply to function and execute operationally in a method that delivers sturdy monetary outcomes. After which secondly, to advance our pipeline. I believe after we take into consideration the momentum of the enterprise and the monetary outcomes, actually, ’25 we’ll announce in a few weeks.
However for those who take it — for those who’ll indulge me and look again a few years, after we have been going into the HUMIRA LOE. Actually, there was plenty of uncertainty as to how that may play out. And we have been very pleased with how the group has labored by that. After we have a look at the 2025 steering that
